InvestorsHub Logo
Followers 145
Posts 27593
Boards Moderated 3
Alias Born 02/07/2004

Re: None

Monday, 05/08/2023 8:52:58 AM

Monday, May 08, 2023 8:52:58 AM

Post# of 3990
Protalix Biotherapeutics

https://finance.yahoo.com/news/weekly-biotech-pulse-big-catalysts-063256242.html

Another day, another PDUFA. On the docket for Tuesday is a PDUFA review for Protalix Biotherapeutics' (NYSE:PLX) PRX-102 compound, its Fabry disease candidate - news that InvestingPro subscribers will get in rapid fire.

Protalix likewise got a CRL back in April 2021 and also appears to have regained some trust among investors ahead of the key decision: Shares have gained just shy of 140% since the start of the year.

The company has 3 buy ratings from analysts, 5 holds, and 0 sells ahead of the decision.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PLX News